Clinical Outcomes in Patients With Faster Advancing MS Treated With Teriflunomide in TEMSO and TOWER

Aaron E Miller,1 Ludwig Kappos,2 Jiwon Oh,2 Karthi Nathan Thangavelu,1 Pascal Rüf,3 Steve Cavaliere,4 Philippe Truffinet,4 Giancarlo Comi5  
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2University Hospital Basel, Basel, Switzerland; 3St Michael's Hospital, Toronto, ON, Canada; 4Sanofi Genzyme, Cambridge, MA, USA; 5Sanofi Genzyme, Chilly-Mazarin, France; 6University Vita-Salute San Raffaele, Milan, Italy

OBJECTIVE
• To investigate the clinical outcomes of teriflunomide-treated patients with faster advancing MS (Multiple Sclerosis Severity Score [MSSS] >5) prior to treatment initiation in the TEMSO and TOWER studies

CONCLUSIONS
- In a pooled subgroup analysis of patients in TEMSO and TOWER who had faster advancing disease, patients treated with teriflunomide had superior efficacy outcomes than patients treated with placebo – patients who had faster advancing MS had significantly reduced the risk of both ≥12-week and ≥24-week confirmed disability worsening  
- Both teriflunomide 7 mg and 14 mg significantly reduced ARR  
These data support the efficacy of teriflunomide in a broad spectrum of patients with RMS, including those with faster advancing disease, and are consistent with efficacy outcomes previously reported for both doses of teriflunomide in the individual studies and the TEMSO/TOWER pool

INTRODUCTION
• Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting MS  
• In 2 pivotal phase 3 trials in patients with relapsing forms of MS (RMS), teriflunomide 14 mg demonstrated consistent efficacy in reducing the risk of disability worsening confirmed for ≥12 weeks (TEMSO, NCT01345435, 29.8% hazard ratio reduction vs placebo, P=0.0279; TOWER, NCT01758181, 31.5% hazard ratio reduction vs placebo, P=0.0442) and in reducing the annualized relapse rate (ARR; TEMSO, 31.5% relative risk reduction vs placebo, P=0.0005; TOWER, 36.3% RR reduction vs placebo, P=0.0001)  
• In TEMSO, teriflunomide 14 mg also demonstrated efficacy on magnetic resonance imaging (MRI) lesion activity in patients with RMS. MRI was not performed in TOWER  
• In both TEMSO and TOWER, teriflunomide 7 mg significantly reduced ARR, but not disability worsening
• Teriflunomide has also been shown to significantly reduce brain volume loss vs placebo over 2 years (teriflunomide 7 mg, 27.6%, P=0.0199; teriflunomide 14 mg, 30.6%, P=0.0001) in a SENA (structural image evaluation using normalization of atrophy) analysis of TEMSO MRI scans, consistent with its positive effects on disability worsening  
• The MSSS integrates disease duration and Expanded Disability Status Scale (EDSS) scores to provide an indication of disease severity, with higher scores reflecting faster advancing disease  
• In a post hoc analysis of pooled data from the TEMSO and TOWER studies, we evaluated clinical outcomes in a subgroup of patients with faster advancing MS, according to disease severity using a baseline MSSS of 5 as a cutoff

METHODS

Study Design
• TEMSO and TOWER were phase 3, multicenter, multinational, randomized, double-blind, parallel-arm, placebo-controlled studies  
• TEMSO and TOWER patients with RMS were randomized 1:1:1 to placebo, teriflunomide 7 mg, or teriflunomide 14 mg. Patients received treatment for 2 years in TEMSO. In TOWER, study duration was variable, ending 48 weeks after the last patient was randomized  
  - Inclusion criteria, and primary and secondary study endpoints for both studies, have been previously described

Subgroup Analyses
• The efficacy of teriflunomide on ARR and disability worsening, confirmed for ≥12 weeks in a subgroup of patients with faster advancing MS, defined as patients with baseline MSSS >5, was evaluated in a post hoc analysis of the pooled TEMSO/TOWER dataset

RESULTS

Patients
• Demographics and baseline disease characteristics for all patients and patients with baseline MSSS >5 in the TEMSO/TOWER pool are shown in Table 1  
• A total of 1,164/2,257 patients (52%) had MSSS >5 at baseline (Table 1)  
  - Compared with the overall TEMSO/TOWER pool, patients with baseline MSSS >5 had higher EDSS scores and a shorter time since diagnosis and first symptoms, with a higher proportion having a progressive MS subtype with superimposed relapses

Annualized Relapse Rate
• Consistent with the significant effects of teriflunomide in the overall study population, ARR was significantly reduced by both doses of teriflunomide in the MSSS >5 subgroup (Figure 3)  
• Time to first relapse was also reduced by both doses of teriflunomide in the MSSS >5 subgroup, with reductions in relapse risk of 43.2% (P=0.0001) and 28% (P=0.001) NRI for teriflunomide 14 mg and 7 mg vs placebo, respectively (Figure 2)

Disability Worsening
• In patients with baseline MSSS >5, teriflunomide 14 mg significantly reduced the risk of both ≥12-week and ≥24-week confirmed disability worsening (Figures 3A and 3B), compared with placebo

Statistical Analysis
• Analysis of ARR was performed using a Poisson model, with the total number of confirmed relapses between the randomization date and start of last study medication intake defined as the response variable; treatment group. EDSS strata at baseline, and region defined as covariates; and top-transformed standardized study duration defined as an offset variable  
• The risk of disability worsening confirmed for ≥12 weeks or ≥24 weeks was evaluated using a Cox proportional hazards model, and log-rank test with EDSS strata at baseline and region as covariates was made to treatment group comparisons. The probability of disability worsening was derived from Kaplan-Meier estimates

Table 1. Demographics and Baseline Disease Characteristics for Patients in the TEMSO/TOWER Pool

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Patients</th>
<th>Patients With Baseline MSSS &gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Patients</td>
<td>405</td>
<td>209</td>
</tr>
<tr>
<td>Age (years)</td>
<td>50 (15–79)</td>
<td>50 (15–79)</td>
</tr>
<tr>
<td>Gender (M:F)</td>
<td>245:160</td>
<td>132:77</td>
</tr>
<tr>
<td>Race</td>
<td>White:Black:Other</td>
<td>349:22:24</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6 (0.1–31)</td>
<td>5 (0.1–29)</td>
</tr>
<tr>
<td>EDSS score</td>
<td>5.5 (1.5–9.5)</td>
<td>5.5 (1.5–9.5)</td>
</tr>
<tr>
<td>MSSS</td>
<td>5 (5–30)</td>
<td>5 (5–30)</td>
</tr>
<tr>
<td>HADS</td>
<td>5 (1–21)</td>
<td>6 (1–21)</td>
</tr>
<tr>
<td>CCS</td>
<td>3 (1–4)</td>
<td>3 (1–4)</td>
</tr>
<tr>
<td>Time since first symptoms, median (min, max)</td>
<td>12 (0, 296)</td>
<td>11 (0, 296)</td>
</tr>
<tr>
<td>Time since first symptoms, mean (SD), years</td>
<td>12 (3.76)</td>
<td>11 (3.76)</td>
</tr>
<tr>
<td>Teriflunomide dose, mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teri 7 mg</td>
<td>29 (72.1%)</td>
<td>150 (100%)</td>
</tr>
<tr>
<td>Teri 14 mg</td>
<td>40 (27.9%)</td>
<td>59 (37.4%)</td>
</tr>
</tbody>
</table>

Teriflunomide 14 mg significantly reduced the risk of both ≥12-week and ≥24-week confirmed disability worsening compared with placebo (teriflunomide 7 mg vs placebo NRI: 43.2%, P=0.0001; teriflunomide 14 mg vs placebo NRI: 28%, P=0.001). In the overall TEMSO/TOWER pool, teriflunomide 7 mg reduced ARR by 31.5% (95% CI, 26.1% to 36.8%) and 14 mg by 36.3% (95% CI, 31.2% to 41.8%) compared with placebo (P<0.0001). The absolute ARR over 2 years (teriflunomide 7 mg, 27.6% and teriflunomide 14 mg, 30.6%) were consistent with the /0.01% in the SENA structural image evaluation using normalization of atrophy analysis of TEMSO MRI scans, consistent with its positive effects on disability worsening

Acknowledgments and Disclosures
- All authors or their immediate families have reported relationships with or have received funds for research, travel, or other activities from Sanofi Genzyme. The other authors report no conflicts of interest

References